Percheron Therapeutics Past Earnings Performance
Past criteria checks 0/6
Percheron Therapeutics's earnings have been declining at an average annual rate of -20.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 37% per year.
Key information
-20.8%
Earnings growth rate
-7.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 37.0% |
| Return on equity | -127.3% |
| Net Margin | -401.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Percheron Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -12 | 4 | 11 |
| 31 Mar 24 | 3 | -11 | 4 | 10 |
| 31 Dec 23 | 2 | -11 | 3 | 10 |
| 30 Sep 23 | 2 | -11 | 3 | 10 |
| 30 Jun 23 | 2 | -11 | 3 | 10 |
| 31 Mar 23 | 2 | -10 | 3 | 9 |
| 31 Dec 22 | 2 | -8 | 3 | 7 |
| 30 Sep 22 | 2 | -7 | 3 | 6 |
| 30 Jun 22 | 2 | -6 | 3 | 5 |
| 31 Mar 22 | 1 | -7 | 4 | 5 |
| 31 Dec 21 | 1 | -9 | 4 | 5 |
| 30 Sep 21 | 1 | -9 | 4 | 5 |
| 30 Jun 21 | 1 | -8 | 4 | 5 |
| 31 Mar 21 | 1 | -6 | 3 | 3 |
| 31 Dec 20 | 1 | -4 | 2 | 2 |
| 30 Sep 20 | 1 | -5 | 3 | 2 |
| 30 Jun 20 | 1 | -6 | 4 | 2 |
| 31 Mar 20 | 1 | -6 | 4 | 2 |
| 31 Dec 19 | 1 | -6 | 4 | 2 |
| 30 Sep 19 | 1 | -4 | 3 | 2 |
| 30 Jun 19 | 1 | -3 | 2 | 2 |
| 31 Mar 19 | 0 | -3 | 2 | 2 |
| 31 Dec 18 | 0 | -3 | 1 | 2 |
| 30 Sep 18 | 0 | -3 | 1 | 1 |
| 30 Jun 18 | 0 | -2 | 1 | 1 |
| 31 Mar 18 | 0 | -2 | 2 | 1 |
| 31 Dec 17 | 0 | -2 | 2 | 1 |
| 30 Sep 17 | 1 | -3 | 2 | 1 |
| 30 Jun 17 | 1 | -3 | 2 | 1 |
| 31 Mar 17 | 1 | -2 | 2 | 1 |
| 31 Dec 16 | 1 | -2 | 2 | 1 |
| 30 Sep 16 | 2 | -2 | 2 | 2 |
| 30 Jun 16 | 2 | -3 | 2 | 2 |
| 31 Mar 16 | 3 | -1 | 2 | 2 |
| 31 Dec 15 | 4 | 1 | 2 | 2 |
| 30 Sep 15 | 5 | 1 | 2 | 2 |
| 30 Jun 15 | 5 | 1 | 2 | 2 |
| 31 Mar 15 | 3 | -1 | 2 | 2 |
| 31 Dec 14 | 1 | -3 | 2 | 2 |
| 30 Sep 14 | 1 | -3 | 2 | 2 |
| 30 Jun 14 | 1 | -3 | 2 | 2 |
| 31 Mar 14 | 1 | -3 | 2 | 2 |
| 31 Dec 13 | 1 | -3 | 2 | 2 |
Quality Earnings: AWY0 is currently unprofitable.
Growing Profit Margin: AWY0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AWY0 is unprofitable, and losses have increased over the past 5 years at a rate of 20.8% per year.
Accelerating Growth: Unable to compare AWY0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AWY0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: AWY0 has a negative Return on Equity (-127.3%), as it is currently unprofitable.